Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention

International Journal of Cardiology

Volumn 150, Issue 1, 2011, Pages 79-83

  Montalescot, Gilles ^a   Salette, Genevieve ^b   Steg, Gabriel ^c   Cohen, Marc ^d   White, Harvey D ^e   Gallo, Richard ^f   Steinhubl, Steven R ^g  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SANOFI   (France)

^c INSERM   (France)

^d NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f MONTREAL HEART INSTITUTE   (Canada)

^g GEISINGER MEDICAL CENTER   (United States)

Author keywords

Bleeding risk; Elective percutaneous coronary intervention; Prediction model

Indexed keywords

ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

AGED; ARTICLE; BLEEDING; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; RISK FACTORS; SURGICAL PROCEDURES, ELECTIVE;

EID: 79960068055     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.02.077     Document Type: Article

References (37)

1. G. Milkovich, and G. Gibson Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention Am J Health Syst Pharm 60 14 Suppl 3 2003 S15 S21
2. D.J. Cohen, A.M. Lincoff, and T.A. Lavelle Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial J Am Coll Cardiol 44 2004 1792 1800 (Pubitemid 39424077)
3. T.D. Kinnaird, E. Stabile, and G.S. Mintz Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions Am J Cardiol 92 2003 930 935 (Pubitemid 37214804)
4. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators S. Yusuf, and S.R. Mehta Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
5. S.V. Rao, J.G. Jollis, and R.A. Harrington Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562 (Pubitemid 39314961)
6. S.V. Rao, K. O'Grady, and K.S. Pieper Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes Am J Cardiol 96 2005 1200 1206 (Pubitemid 41505393)
7. G. Montalescot, H.D. White, and R. Gallo Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention N Engl J Med 355 2006 1006 1017 (Pubitemid 44343544)
8. S.R. Mehta, P.G. Steg, and C.B. Granger Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) pilot trial Circulation 111 2005 1390 1397 (Pubitemid 40396805)
9. A.M. Lincoff, J.A. Bittl, and R.A. Harrington Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863 (Pubitemid 37430344)
10. G. Montalescot, Z. Ongen, and R. Guindy Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study Int J Cardiol 129 2008 379 387
11. E. Nikolsky, R. Mehran, and G. Dangas Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach Eur Heart J 28 2007 1936 1945 (Pubitemid 47579535)
12. E.M. Antman, M. Cohen, and P.J. Bernink The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making JAMA 284 2000 835 842 (Pubitemid 30643610)
13. E. Boersma, K.S. Pieper, and E.W. Steyerberg Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators Circulation 101 2000 2557 2567 (Pubitemid 30350632)
14. C.B. Granger, R.J. Goldberg, and O. Dabbous Predictors of hospital mortality in the Global Registry of Acute Coronary Events Arch Intern Med 163 2003 2345 2353 (Pubitemid 37310196)
15. K.A. Fox, O.H. Dabbous, and R.J. Goldberg Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 333 2006 1091 1094 (Pubitemid 44863647)
16. K.A. Eagle, M.J. Lim, and O.H. Dabbous A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733 (Pubitemid 38725422)
17. S.K. Mehta, A.D. Frutkin, and J.B. Lindsey On behalf of the National Cardiovascular Data Registry. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry Circ Cardiovasc Intervent 2 2009 222 229
18. D.W. Hosmer Jr., and S. Lemeshow Applied logistic regression: probability & mathematical statistics 1989 John Wiley & Sons New York
19. S.C. Smith Jr., T.E. Feldman, and J.W. Hirshfeld Jr. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/SCAI Writing Committee to update 2001 Guidelines for Percutaneous Coronary Intervention) Circulation 113 2006 e166 e286
20. A.J. Lansky, C. Pietras, and R.A. Costa Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial Circulation 111 2005 1611 1618 (Pubitemid 40525160)
21. L.S. Fernandes, J.E. Tcheng, and J.C. O'Shea Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study J Am Coll Cardiol 40 2002 1085 1091
22. L. Cho, E.J. Topol, and C. Balog Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the prevention of ischemic complications. Evaluation in percutaneous transluminal coronary angioplasty to improve long-term outcome with Abciximab GP IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stent J Am Coll Cardiol 36 2000 381 386
23. E. Argulian, A.D. Patel, and J.L. Abramson Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions Am J Cardiol 98 2006 48 53 (Pubitemid 43902676)
24. A.K. Jacobs, J.M. Johnston, and A. Haviland Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry J Am Coll Cardiol 39 2002 1608 1614 (Pubitemid 34494283)
25. J.S. Mandak, J.C. Blankenship, and L.H. Gardner Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to minimize platelet aggregation and coronary thrombosis J Am Coll Cardiol 31 1998 1518 1524 (Pubitemid 28273293)
26. T. Robertson, E.D. Kennard, and S. Mehta Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the New Approaches to Coronary Intervention (NACI) registry Am J Cardiol 80 1997 26K 39K (Pubitemid 28012260)
27. F.K. Welty, S.M. Lewis, W. Kowalker, and S.J. Shubrooks Jr. Reasons for higher in-hospital mortality > 24 hours after percutaneous transluminal coronary angioplasty in women compared with men Am J Cardiol 88 2001 473 477 (Pubitemid 32778489)
28. F. Feit, M.D. Voeltz, and M.J. Attubato Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial Am J Cardiol 100 2007 1364 1369 (Pubitemid 47576015)
29. S. Subherwal, and Chen A.Y. Bach RG The CRUSADE bleeding score to assess baseline risk of major bleeding in non-ST-segment elevation myocardial infarction J Am Coll Cardio Suppl A 2008 A212
30. E. Karvouni, D.G. Katritsis, and J.P. Ioannidis Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J Am Coll Cardiol 41 2003 26 32 (Pubitemid 36044399)
31. R. Choussat, G. Montalescot, and J.P. Collet A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention J Am Coll Cardiol 40 2002 1943 1950 (Pubitemid 35425364)
32. D.J. Kereiakes, C. Grines, and E. Fry National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention J Invasive Cardiol 13 2001 272 278 (Pubitemid 33759464)
33. G. Montalescot, S. Steinhubl, and W. Desmet Lack of correlation between ACT levels and outcomes in patients undergoing elective percutaneous coronary intervention with unfractionated heparin: the STEEPLE trial Eur Heart J Abstract Suppl 2006 645
34. G. Montalescot, M. Cohen, and G. Salette Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial Eur Heart J 29 2008 462 471 (Pubitemid 351264194)
35. A.J. Kirtane, G. Piazza, and S.A. Murphy Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial J Am Coll Cardiol 47 2006 2374 2379 (Pubitemid 43866383)
36. A.S. Mathis, and J.J. Gugger Percutaneous coronary intervention-related bleeding risk factors in current practice Ann Pharmacother 39 2005 1627 1633 (Pubitemid 41393120)
37. A.J. Coates Ethical authorship and publishing Int J Cardiol 131 2009 149 150